Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Human Papillomavirus DNA Methylation Predicts Response to Treatment Using Cidofovir and Imiquimod in Vulval Intraepithelial Neoplasia 3.

Jones SEF, Hibbitts S, Hurt CN, Bryant D, Fiander AN, Powell N, Tristram AJ.

Clin Cancer Res. 2017 Sep 15;23(18):5460-5468. doi: 10.1158/1078-0432.CCR-17-0040. Epub 2017 Jun 9.

2.

Geographical distribution and risk association of human papillomavirus genotype 52-variant lineages.

Zhang C, Park JS, Grce M, Hibbitts S, Palefsky JM, Konno R, Smith-McCune KK, Giovannelli L, Chu TY, Picconi MA, Piña-Sánchez P, Settheetham-Ishida W, Coutlée F, De Marco F, Woo YL, Ho WC, Wong MC, Chirenje MZ, Magure T, Moscicki AB, Sabol I, Fiander AN, Chen Z, Chan MC, Cheung TH, Burk RD, Chan PK.

J Infect Dis. 2014 Nov 15;210(10):1600-4. doi: 10.1093/infdis/jiu310. Epub 2014 May 30.

3.

Human papillomavirus infection is rare in nonmalignant tonsil tissue in the UK: implications for tonsil cancer precursor lesions.

Palmer E, Newcombe RG, Green AC, Kelly C, Noel Gill O, Hall G, Fiander AN, Pirotte E, Hibbitts SJ, Homer J, Powell NG.

Int J Cancer. 2014 Nov 15;135(10):2437-43. doi: 10.1002/ijc.28886. Epub 2014 Apr 18.

4.

Framing patient consent for student involvement in pelvic examination: a dual model of autonomy.

Carson-Stevens A, Davies MM, Jones R, Chik AD, Robbé IJ, Fiander AN.

J Med Ethics. 2013 Nov;39(11):676-80. doi: 10.1136/medethics-2012-100809. Epub 2013 Jan 15.

PMID:
23322682
5.

Geographical distribution and oncogenic risk association of human papillomavirus type 58 E6 and E7 sequence variations.

Chan PK, Zhang C, Park JS, Smith-McCune KK, Palefsky JM, Giovannelli L, Coutlée F, Hibbitts S, Konno R, Settheetham-Ishida W, Chu TY, Ferrera A, Alejandra Picconi M, De Marco F, Woo YL, Raiol T, Piña-Sánchez P, Bae JH, Wong MC, Chirenje MZ, Magure T, Moscicki AB, Fiander AN, Capra G, Young Ki E, Tan Y, Chen Z, Burk RD, Chan MC, Cheung TH, Pim D, Banks L.

Int J Cancer. 2013 Jun 1;132(11):2528-36. doi: 10.1002/ijc.27932. Epub 2012 Nov 29.

6.
7.

Identification of human papillomavirus type 58 lineages and the distribution worldwide.

Chan PK, Luk AC, Park JS, Smith-McCune KK, Palefsky JM, Konno R, Giovannelli L, Coutlée F, Hibbitts S, Chu TY, Settheetham-Ishida W, Picconi MA, Ferrera A, De Marco F, Woo YL, Raiol T, Piña-Sánchez P, Cheung JL, Bae JH, Chirenje MZ, Magure T, Moscicki AB, Fiander AN, Di Stefano R, Cheung TH, Yu MM, Tsui SK, Pim D, Banks L.

J Infect Dis. 2011 Jun 1;203(11):1565-73. doi: 10.1093/infdis/jir157.

8.

Development of optimal liquid based cytology sample processing methods for HPV testing: minimising the 'inadequate' test result.

Peevor R, Jones J, Fiander AN, Hibbitts S.

J Virol Methods. 2011 May;173(2):374-7. doi: 10.1016/j.jviromet.2011.01.020. Epub 2011 Feb 3.

PMID:
21295606
9.

The prevention of cervical cancer in Africa.

Fiander AN.

Womens Health (Lond). 2011 Jan;7(1):121-32. doi: 10.2217/whe.10.74. Review.

PMID:
21175396
10.

The risk of cervical cancer associated with specific types of human papillomavirus: a case-control study in a UK population.

Powell NG, Hibbitts SJ, Boyde AM, Newcombe RG, Tristram AJ, Fiander AN.

Int J Cancer. 2011 Apr 1;128(7):1676-82. doi: 10.1002/ijc.25485. Epub 2010 May 25.

11.

Comparison of the PapilloCheck DNA micro-array Human Papillomavirus detection assay with Hybrid Capture II and PCR-enzyme immunoassay using the GP5/6+ primer set.

Jones J, Powell NG, Tristram A, Fiander AN, Hibbitts S.

J Clin Virol. 2009 Jun;45(2):100-4. doi: 10.1016/j.jcv.2009.02.013. Epub 2009 Apr 24.

PMID:
19394266
12.

Leiomyosarcoma following uterine artery embolisation.

Naeem S, Aitkens L, Evans AS, Fiander AN.

J Obstet Gynaecol. 2009 Jan;29(1):74-7. doi: 10.1080/01443610802628924. No abstract available.

PMID:
19280513
13.

Human Papillomavirus negative but dyskaryotic cervical cytology: re-analysis of molecular testing.

Peevor R, Bowden S, Jones J, Fiander AN, Hibbitts S.

J Clin Virol. 2009 Apr;44(4):322-4. doi: 10.1016/j.jcv.2009.01.015. Epub 2009 Mar 4.

PMID:
19264544
14.

Human papillomavirus prevalence in women attending routine cervical screening in South Wales, UK: a cross-sectional study.

Hibbitts S, Jones J, Powell N, Dallimore N, McRea J, Beer H, Tristram A, Fielder H, Fiander AN.

Br J Cancer. 2008 Dec 2;99(11):1929-33. doi: 10.1038/sj.bjc.6604748. Epub 2008 Oct 28.

15.

Human papillomavirus infection in Barrett's oesophagus in the UK: an infrequent event.

Rai N, Jenkins GJ, McAdam E, Hibbitts SJ, Fiander AN, Powell NG.

J Clin Virol. 2008 Oct;43(2):250-2. doi: 10.1016/j.jcv.2008.07.004. Epub 2008 Aug 21.

PMID:
18718811
16.

Contribution of demographic, psychological and disease-related factors to quality of life in women with high-grade vulval intraepithelial neoplasia.

Shylasree TS, Karanjgaokar V, Tristram A, Wilkes AR, MacLean AB, Fiander AN.

Gynecol Oncol. 2008 Aug;110(2):185-9. doi: 10.1016/j.ygyno.2008.04.023. Epub 2008 Jun 3.

PMID:
18533238
17.

Will vaccination against human papillomavirus prevent eye disease? A review of the evidence.

Hughes DS, Powell N, Fiander AN.

Br J Ophthalmol. 2008 Apr;92(4):460-5. doi: 10.1136/bjo.2007.135038. Review.

PMID:
18369059
18.

HPV16 E6 29-38-specific T cells kill cervical carcinoma cells despite partial evasion of T-cell effector function.

Thomas KJ, Smith KL, Youde SJ, Evans M, Fiander AN, Borysiewicz LK, Man S.

Int J Cancer. 2008 Jun 15;122(12):2791-9. doi: 10.1002/ijc.23475.

19.

Cervical screening in young women aged 20-24 years.

Fiander AN.

J Fam Plann Reprod Health Care. 2008 Jan;34(1):19. doi: 10.1783/147118908783332104. No abstract available.

20.
21.

Variation in human papillomavirus type-16 viral load within different histological grades of cervical neoplasia.

Fiander AN, Hart KW, Hibbitts SJ, Rieck GC, Tristram AJ, Beukenholdt RW, Powell NG.

J Med Virol. 2007 Sep;79(9):1366-9.

PMID:
17607770
22.

Human papillomavirus infection: an anonymous prevalence study in South Wales, UK.

Hibbitts S, Rieck GC, Hart K, Powell NG, Beukenholdt R, Dallimore N, McRea J, Hauke A, Tristram A, Fiander AN.

Br J Cancer. 2006 Jul 17;95(2):226-32. Epub 2006 Jul 4.

23.

Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial.

Fiander AN, Tristram AJ, Davidson EJ, Tomlinson AE, Man S, Baldwin PJ, Sterling JC, Kitchener HC.

Int J Gynecol Cancer. 2006 May-Jun;16(3):1075-81.

PMID:
16803488
24.

Cervical screening in 20-24-year olds.

Rieck GC, Tristram A, Hauke A, Fielder H, Fiander AN.

J Med Screen. 2006;13(2):64-71; discussion 62-3.

PMID:
16792827
25.

Power Doppler in the assessment of pelvic masses in a low risk group.

Rieck GC, Pugh ND, Fiander AN.

J Obstet Gynaecol. 2006 Apr;26(3):222-4.

PMID:
16698629
26.

Screening for familial ovarian cancer--management and outcome of women with moderate to high risk of developing ovarian cancer.

Rieck GC, Lim K, Rogers MT, France E, Gray JR, Amso N, Evans AS, Howells RH, Fiander AN.

Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:86-91.

PMID:
16515573
27.

Cervical human papillomavirus infection and squamous intraepithelial lesions in rural Gambia, West Africa: viral sequence analysis and epidemiology.

Wall SR, Scherf CF, Morison L, Hart KW, West B, Ekpo G, Fiander AN, Man S, Gelder CM, Walraven G, Borysiewicz LK.

Br J Cancer. 2005 Oct 31;93(9):1068-76.

28.

Epitope specificity and longevity of a vaccine-induced human T cell response against HPV18.

Smith KL, Tristram A, Gallagher KM, Fiander AN, Man S.

Int Immunol. 2005 Feb;17(2):167-76. Epub 2004 Dec 27.

PMID:
15623547
29.

Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination.

Smyth LJ, Van Poelgeest MI, Davidson EJ, Kwappenberg KM, Burt D, Sehr P, Pawlita M, Man S, Hickling JK, Fiander AN, Tristram A, Kitchener HC, Offringa R, Stern PL, Van Der Burg SH.

Clin Cancer Res. 2004 May 1;10(9):2954-61.

30.

Sebaceous carcinoma of the vulva.

Khan Z, Misra G, Fiander AN, Dallimore NS.

BJOG. 2003 Feb;110(2):227-8. No abstract available.

31.

Novel method for detection, typing, and quantification of human papillomaviruses in clinical samples.

Hart KW, Williams OM, Thelwell N, Fiander AN, Brown T, Borysiewicz LK, Gelder CM.

J Clin Microbiol. 2001 Sep;39(9):3204-12.

32.
33.

Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intraepithelial neoplasia grade III.

Nimako M, Fiander AN, Wilkinson GW, Borysiewicz LK, Man S.

Cancer Res. 1997 Nov 1;57(21):4855-61.

34.

Cytotoxic T cell immunity to human cytomegalovirus glycoprotein B.

Hopkins JI, Fiander AN, Evans AS, Delchambre M, Gheysen D, Borysiewicz LK.

J Med Virol. 1996 Jun;49(2):124-31.

PMID:
8991935
35.

Immunocompetent for immunotherapy? A study of the immunocompetence of cervical cancer patients.

Fiander AN, Adams M, Evans AS, Bennett AJ, Borysiewicz LK.

Int J Gynecol Cancer. 1995 Nov;5(6):438-442.

PMID:
11578518
36.

The airway in the upright anaesthetised patient.

Ball HC, Fiander AN.

Br Dent J. 1981 Aug 18;151(4):111. No abstract available.

PMID:
6942864

Supplemental Content

Loading ...
Support Center